Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lutetium-177-CTR-FAPI (also known as 177Lu-BRP-010030) is an innovative, covalent-engineered radiopharmaceutical therapy (RLT) developed by Boomray Pharmaceuticals in collaboration with Peking University. It consists of a fibroblast activation protein inhibitor (FAPI) conjugated to the beta-emitting radioisotope lutetium-177 (177Lu). Unlike conventional FAPI ligands that bind reversibly, lutetium-177-CTR-FAPI utilizes a proprietary Covalent Targeted Radioligand (CTR) technology platform with a sulfur(VI)-fluoride exchange (SuFEx) chemical warhead. This allows the molecule to form an irreversible covalent bond with the tyrosine residues of fibroblast activation protein (FAP) overexpressed on cancer-associated fibroblasts (CAFs) in the tumor microenvironment. This covalent anchoring results in significantly higher tumor uptake, prolonged intratumoral retention, and enhanced therapeutic efficacy with manageable systemic toxicity. The drug is currently in Phase 1 clinical development for the treatment of FAP-expressing advanced solid tumors, including thyroid cancer, breast cancer, sarcoma, and gastrointestinal malignancies.
| Indication | Highest phase | Status |
|---|---|---|
| breast cancer and precursor lesions | In development | Active |
| gastrointestinal cancers and precursor lesions | In development | Active |
| liver and biliary tract cancers and premalignant lesions | In development | Active |
| soft-tissue sarcomas | In development | Active |
| thyroid cancer and precursor lesions | In development | Active |
Every indication, with countries and timelines, is in the full profile.
| Market | Status | Year |
|---|---|---|
| United States | Not approved | — |
| European Union | Not approved | — |
| China | Not approved | — |
| Japan | Not approved | — |
Approved indications and other markets are in the full profile.
Lead indication: breast cancer and precursor lesions
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lutetium-177-CTR-FAPI.
Work on lutetium-177-CTR-FAPI? Claim this page to correct or add information. Claim this page